<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04026347</url>
  </required_header>
  <id_info>
    <org_study_id>CD1010</org_study_id>
    <nct_id>NCT04026347</nct_id>
  </id_info>
  <brief_title>Vesair Clinical Trial</brief_title>
  <acronym>VAPOR</acronym>
  <official_title>An Evaluation of the VesairÂ® Bladder Control System for the Treatment of Stress Urinary Incontinence in Post-Menopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Solace Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Solace Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-blind, multicenter, randomized clinical trial of the Vesair Balloon in the treatment&#xD;
      of Stress Urinary Incontinence in post-menopausal women&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Subject and assessor blinded to randomization result</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Endpoint</measure>
    <time_frame>6 months</time_frame>
    <description>Pad weight + I-QOL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pad Weight</measure>
    <time_frame>6 months</time_frame>
    <description>Reduction in pad weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>I-QOL</measure>
    <time_frame>6 months</time_frame>
    <description>Improvement in I-QOL score (0-100 point scale, 100 being the best outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episode Frequency</measure>
    <time_frame>6 months</time_frame>
    <description>Reduction in episode frequency as reported on a 7 day diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Improvement (PGI-I)</measure>
    <time_frame>6 months</time_frame>
    <description>Significant Improvement per PGI-I (response of very much better or much better on 7 point scale)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">158</enrollment>
  <condition>Stress Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Vesair</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects are treated with Vesair Balloon at enrollment (day 0)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Subjects are treated with sham at enrollment (day 0) and treated with balloon (if desired) after six month visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vesair Balloon</intervention_name>
    <description>Indwelling, intravesical balloon</description>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_label>Vesair</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham balloon placement</intervention_name>
    <description>Sham balloon placement procedure</description>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Post-menopausal women with SUI for at least 12 months&#xD;
&#xD;
          -  Average of at least one leak per day&#xD;
&#xD;
          -  Failed non-invasive treatment&#xD;
&#xD;
          -  Willing to undergo cystoscopy and a minimum of 5 visits over one year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI &gt; 40.0&#xD;
&#xD;
          -  Last menstrual period within 12 months of enrollment&#xD;
&#xD;
          -  On birth control and/or oral hormone replacement therapy&#xD;
&#xD;
          -  Urge-predominant mixed incontinence&#xD;
&#xD;
          -  SUI due to intrinsic sphincter deficiency&#xD;
&#xD;
          -  Prior treatment with the Vesair Balloon&#xD;
&#xD;
          -  Prior medical, surgical or non-surgical treatment for SUI within 6 months of&#xD;
             enrollment&#xD;
&#xD;
          -  Recurrent or recent (within the past 5 years) kidney stones&#xD;
&#xD;
          -  Recurrent or recent (within the past 3 months) Urinary Tract Infection&#xD;
&#xD;
          -  Stage 3 or higher cystocele (POP-Q)&#xD;
&#xD;
          -  Interstitial or follicular cystitis / painful bladder syndrome&#xD;
&#xD;
          -  Local genital infection&#xD;
&#xD;
          -  Artificial sphincter&#xD;
&#xD;
          -  Anatomic abnormalities which would interfere with device placement.&#xD;
&#xD;
          -  Visible blood in the urine&#xD;
&#xD;
          -  Uncontrolled bladder contractions / discomfort with bladder filling up to 300cc&#xD;
&#xD;
          -  History of cancer of the urinary tract&#xD;
&#xD;
          -  History of any cancer within the past two years (excluding non-melanoma skin cancers)&#xD;
&#xD;
          -  History of any cancer not (yet) treated with curable intent (excluding non-melanoma&#xD;
             skin cancers)&#xD;
&#xD;
          -  Immunologically suppressed or immunocompromised&#xD;
&#xD;
          -  Undergoing pelvic radiation, pelvic fibrosis from previous pelvic radiation&#xD;
&#xD;
          -  Non ambulatory / unable to do simple pad weight testing exercises&#xD;
&#xD;
          -  On anticoagulation therapy with the exception of aspirin&#xD;
&#xD;
          -  History of mental illness requiring inpatient treatment&#xD;
&#xD;
          -  Neurological disease such as Parkinson's or multiple sclerosis&#xD;
&#xD;
          -  Uncontrolled diabetes (A1C &gt; 9%)&#xD;
&#xD;
          -  Recent alcohol or drug abuse requiring treatment in the past year&#xD;
&#xD;
          -  Autoimmune or connective tissue disorders such as Marfan syndrome, Ehlers-Danlos or&#xD;
             Myasthenia Gravis&#xD;
&#xD;
          -  Allergy to polyurethane or perfluorocarbons&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Valley Urogynecology Associates</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Clinic</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri Valley Urology</name>
      <address>
        <city>Temecula</city>
        <state>California</state>
        <zip>92592</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Health Specialty Care</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Urology Partners</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WomanCare</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMB Research / Basinski and Juran MDs</name>
      <address>
        <city>Newburgh</city>
        <state>Indiana</state>
        <zip>47630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Urology</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology</name>
      <address>
        <city>Hanover</city>
        <state>Maryland</state>
        <zip>21076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology</name>
      <address>
        <city>Owings Mills</city>
        <state>Maryland</state>
        <zip>21117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Health</name>
      <address>
        <city>Ada</city>
        <state>Michigan</state>
        <zip>49301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freedman Urology</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ProHEALTH Garden City Urology</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Medical Group of the Hudson Valley</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Urologists of North Carolina</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women and Infants dept of Urogynecology</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology of Virginia</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.solacetx.com</url>
    <description>Company Website</description>
  </link>
  <link>
    <url>http://www.laughwithoutleaks.com</url>
    <description>Study Website</description>
  </link>
  <results_reference>
    <citation>McCammon K, Jacoby K, Kalota S, Snyder J, Cline K, Robertson K, Rardin C, Kahan R, Green L, Zuckerman J, Rovner E. Three-month primary efficacy data for the SUCCESS Trial; a phase III, multi-center, prospective, randomized, controlled study treating female stress urinary incontinence with the vesair intravesical balloon. Neurourol Urodyn. 2018 Jan;37(1):440-448. doi: 10.1002/nau.23324. Epub 2017 Nov 2.</citation>
    <PMID>29095516</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 17, 2019</study_first_submitted>
  <study_first_submitted_qc>July 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2019</study_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SUI</keyword>
  <keyword>Women</keyword>
  <keyword>Incontinence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

